The era of genomics and precision medicine holds the promise of revolutionizing the prevention and treatment of disease. Precision medicine uses information at the genetic level to predict likelihood of disease or response to therapy. As precision medicine continues to emerge as the diagnostic pathway of choice for such diseases as cancer, questions have emerged regarding how best to democratize the technology to benefit most people. The cost of next generation sequencing (NGS), a laboratory method that elucidates targeted subsets of the genome in a single test, continues to decline. However, the expertise to appropriately interpret the data output remains elusive to most institutions wishing to adopt or scale their test offerings. The association of genomic findings unique to each patient with targeted therapies is at the same time the greatest value and challenge in the precision medicine era. GenoTech Diagnostics, LLC will seek to facilitate and streamline annotation of NGS data focusing on medical providers in the greater Los Angeles area. This clinical decision support business will reside at the nexus of medicine and technology, providing accessible, accurate, and comprehensive interpretation of data generated from NGS profiling of solid tumors.